- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03718494
Continuation of The Kronos Early Estrogen Prevention Study (KEEPS) (KEEPS)
Prevention of Alzheimer's Disease in Women: Risks and Benefits of Hormone Therapy -Continuation of: "The Kronos Early Estrogen Prevention Study (KEEPS)"
Study Overview
Status
Conditions
Detailed Description
This is a continuation of the Kronos Early Estrogen Prevention Study (KEEPS) (KEEPS; NCT00154180), a multicenter double blinded, placebo-controlled, randomized trial funded by the Kronos Longevity Research Institute, Phoenix, AZ to test the hypothesis that hormone therapy started early in menopause (within the "window of opportunity") would slow progression of atherosclerosis as measured by changes in carotid artery intima-medial thickening and coronary arterial calcification.
This study will involve a single follow-up evaluation of brain imaging and cognitive function of women who were randomized to menopausal hormone therapy (mHT) or placebo, approximately 13 years post-randomization and nine years after the end of mHT administration phase in KEEPS (NCT00154180). No interventions are given as part of this study; any current hormonal treatments are by choice and prescribed by the participant's personal physician.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85032
- Banner Health
-
-
California
-
San Francisco, California, United States, 94158
- University of California San Francisco
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
New York
-
New York, New York, United States, 10027
- Columbia University
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participated in the original KEEPS trial.
- Able to understand study procedures.
- Willing to sign an authorization of consent in order to participate in this study.
Exclusion Criteria:
• Women who have contraindications to MRI or PET for safety reasons, such as an MRI-incompatible implant or claustrophobia.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Menopausal Hormone Therapy (mHT) Group
Women that participated in and completed the KEEPS study (NCT00154180) that were randomized to receive menopausal hormone therapy (mHT) will have a follow up brain Positron Emission Tomography (PET) imaging (F-18 Florbetapir PET or F-18 AV-1451 PET) and cognitive function testing.
|
Performed on a single 3T system and sequences will be acquired in a single sitting with an exam time under 45 minutes.
After a 50-minute uptake period, the patient will be positioned on the scanner bed with instructions to remain motionless.
Injection of 10 mCi of 18F-Florbetapir (target dose 370 MBq, range 296 - 444 MBq) given.
A helical CT image will be obtained at 50 minutes after injection of 18F-Florbetapir, followed by a 20-minute PET acquisition consisting of four 5-minute dynamic frames.
Intravenous bolus injection of approximately 370 MBq (10 mCi) of 18F- AV-1451 (approved under IND 124449).
PET/CT image acquisition will include a low dose CT and then a 20-minute PET acquisition starting at 50-60 minutes after injection of 18F-T807 and will be performed as 4, 5-minute frames that will then be summed into one static frame.
Serial frames will allow for adjustment in the case of patient motion.
A comprehensive battery of standardized neuropsychological tests administered by trained personnel.
|
Placebo Group
Women that participated in and completed the KEEPS study (NCT00154180) that were randomized to receive placebo treatment will have a follow up brain Positron Emission Tomography (PET) imaging (F-18 Florbetapir PET or F-18 AV-1451 PET) and cognitive function testing.
|
Performed on a single 3T system and sequences will be acquired in a single sitting with an exam time under 45 minutes.
After a 50-minute uptake period, the patient will be positioned on the scanner bed with instructions to remain motionless.
Injection of 10 mCi of 18F-Florbetapir (target dose 370 MBq, range 296 - 444 MBq) given.
A helical CT image will be obtained at 50 minutes after injection of 18F-Florbetapir, followed by a 20-minute PET acquisition consisting of four 5-minute dynamic frames.
Intravenous bolus injection of approximately 370 MBq (10 mCi) of 18F- AV-1451 (approved under IND 124449).
PET/CT image acquisition will include a low dose CT and then a 20-minute PET acquisition starting at 50-60 minutes after injection of 18F-T807 and will be performed as 4, 5-minute frames that will then be summed into one static frame.
Serial frames will allow for adjustment in the case of patient motion.
A comprehensive battery of standardized neuropsychological tests administered by trained personnel.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Aβ PET SUVR
Time Frame: 4 years
|
This measure is derived from a PET imaging study that images the deposition of the amyloid plaques of Alzheimer's disease in the brain
|
4 years
|
WMH volume
Time Frame: 4 years
|
This measure is derived from an MRI study that images the brain structure.
WMH is measured from specific regions of the brain that are vulnerable to cerebrovascular disease related injury.
|
4 years
|
Regional cortical thickness
Time Frame: 4 years
|
This measure is derived from an MRI study that images the brain structure.
The cortical thickness is measured from specific regions of the brain that are vulnerable to Alzheimer's disease related neurodegeneration.
|
4 years
|
AV-1451
Time Frame: 4 years
|
This measure is derived from a PET imaging study that images the deposition of the tau protein of Alzheimer's disease in the brain
|
4 years
|
Global cognitive function
Time Frame: 4 years
|
This measurement is derived from multiple neuropsychometric tests that measure various cognitive abilities.
|
4 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kejal Kantarci, M.D., Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-008697
- 1RF1AG057547-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Dementia
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
Hebrew SeniorLifeRecruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Istanbul University - Cerrahpasa (IUC)Not yet recruitingDementia, Alzheimer Type | Alzheimer's Disease | Alzheimer DementiaTurkey
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka America PharmaceuticalCompleted
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Dementia, Alzheimer Type | Dementia Alzheimers | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Dementia, MildUnited States
-
Genescient CorporationCompletedAlzheimer Disease | Alzheimer Dementia
-
Kırıkkale UniversityNot yet recruiting
-
University Medicine GreifswaldTerminated
-
The Hong Kong Polytechnic UniversityUnknown
Clinical Trials on Brain Magnetic Resonance Imaging (MRI)
-
University Hospital, BordeauxTerminatedMild Traumatic Brain InjuryFrance
-
University Hospital OstravaUniversity of Ostrava; České Budějovice HospitalRecruiting
-
Imperial College LondonBiogen; InvicroCompletedInflammatory Response | Stroke, Ischemic | Stroke, AcuteUnited Kingdom
-
Nationwide Children's HospitalSanfilippo Children's Research Foundation; The Sanfilippo Research Foundation; The Children's Medical Research FoundationCompletedMucopolysaccharidosis Type IIIA | Mucopolysaccharidosis Type IIIBUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingProstate CarcinomaUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)WithdrawnUnspecified Adult Solid Tumor, Protocol Specific | Tumors Metastatic to BrainUnited States
-
University of MichiganPhilips Healthcare; General ElectricCompleted
-
American College of RadiologyPennsylvania Department of HealthCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting